Happy 4th Miami.
All one needs do is read the 10Q, discussion section. They spell out in every day terms how they got their revenue, and why it was up or down. So estimates are just plug in those numbers, plus add 10%, or guesstimate on a new revenue source. The analysts are not even close to each other at this point. Over next 6 months no less than 4 revenue streams should kick in. Rolapitant milestone and sales, Eirgen sales, brli sales, and 4k now has a cpt code. Think you will see small inhaler revenue by q4, not yet announced. One of Frost's recent investments ( plum? )has a drug that could use this device, so throwing it out there.
The sales were code f, which is a sale to cover taxes from either current or prior options, those many times are automatic. Curious is those that did not cover the income with an automatic sale, guess they hope the price recovers and they can cover taxes with a sale later selling fewer shares.
Past 4 years oops, your original trash, up 100%, this guy needs go.
My bad ytd arry up 45.67, Ichan's chk down 44.96, 1 year Arry up 62.11%, Carl's chk down 64.56%. Since 2012, Arry up 236%, chk down 55.09%. Arguably the best investor, in the past 20 years, made 1 Billion on netflix should hire RON to run rig and chk.
RON milking the company? HE is one of the lowest paid generals out there, could make far more working for Carl.
This stock will move on news. Carl Ichan owns a TON, of rig and well over 10% of chk, think about that for a second. Does he pound the table on those assets, no, and why? Chk is at maybe a 12 year low, Carl is out a billion, so what should he do? Has not bought in months, etc. CHK will move on nat gas, and lng, as arry will move on phase 3. If Carl can not stop 13 new lows, he should hire RON, arry is up 50% chk down 50% or more.
We cordially invite you to attend a special meeting of shareholders of Bio-Reference Laboratories, Inc., a New Jersey corporation, which we refer to as Bio-Reference, to be held on [●][●], 2015, [●] a.m.,
local time, at the Sheraton Crossroads Hotel, Crossroads Corporate Center, One International Boulevard, Route 17 North, Mahwah, New Jersey 07495-0001. As previously announced, Bio-Reference and OPKO
Health, Inc., a Delaware corporation, which we refer to as OPKO, have entered into an Agreement and Plan of Merger, dated as of June 3, 2015, which we refer to as the merger agreement. Pursuant to the terms of
the merger agreement, a subsidiary of OPKO will merge with and into Bio-Reference, with Bio-Reference surviving the merger as a wholly owned subsidiary of OPKO.
If the merger contemplated by the merger agreement is completed, holders of Bio-Reference common stock will be entitled to receive 2.75 shares of OPKO common stock for each share, etc...
I did look for, but saw no sec filing, to get the real picture. Based on your comment I am thinking they retired 840m worth of preferred, not the whole 1.025B. Regardless, it is ALL good, an sec filing will clarify all. Just wondering now, if they will need do a filing, since these subsidiaries were basically owned by this preferred share group. Never easy, and with NO chk news release, speculation happens.
I was just quoting Morningstar, at first glance many, myself included thought chk would get all the cash. So if they are getting 90m, plus 1B preferred and eliminating 75m in divi payments, that is all good. Read the preferred divi equals .11 per shares annual, but forget where I saw that.
Net neutral 50-100M in ebitda lost, save 75m in preferred dividends. However the 840m goes to the third party. They in essence did a 1.025 billion preferred share buyback.
As we anticipated, on July 1 Chesapeake Energy signed a definitive agreement to sell its Cleveland-Tonkawa, or C-T, assets to privately held FourPoint Energy for $840 million, according to a press release put out by FourPoint (Chesapeake has yet to officially announce the deal).
Given that the C-T assets were held in a separate investment vehicle capitalized primarily by third-party preferred stock, the cash impact to Chesapeake appears to be neutral. As we understand it, Chesapeake will shed approximately 21 Mboe/d of production, or 3% of 2015 volumes--which we estimate would have generated between $50 million and $100 million of full-year EBITDA--in exchange for the elimination of $1.025 billion in preferred stock, which received cash dividends of $75 million annually.
Accordingly, we don’t expect any meaningful change to our fair value estimate once we incorporate the July 1 transaction into our model (we await additional color from Chesapeake before doing so). Our narrow moat rating also remains intact.
The time frame is second half 2015. No dancing in the street, or pumping by Ron can change that fact. If arry was a newly issued stock with this pipeline, yes it would be trading much much higher. Fact is, arry is heavily owned by funds, is an older biotech that has technology no one is pumping any more. The only thing that can get this in hyper drive is phase 3 data, well, or a merger for a quick pop. If their pipeline was full of cart T cell immunotherapies, and phase 3 data was due, yes 100-200 on the hype. Mek inhibitors likely has their niche, but they are not blockbuster type drugs, or cures. Look at bluebio, their technology warrants their lofty price even with only a phase 1 read out.
Arry should still get into the teens if when phase data hits, until then, either be patient, or sell, but whining daily about things beyond the CEO's control is a waste of energy and a waste of your time. I say your time because I know you whiners are still here, I have put all whiners on ignore, so I do not waste my time.
So, sell, short, or go long, and live with your choice as an adult. No one twisted your arm to invest, or gamble on this company, good luck.
Heat in the NE heading to high 80's over next 10 days. Part of the problem with nat gas pricing is that any draw down is really an illusion. Fact is, if there were a massive draw down, there is so much sitting there the draw down could be over supply in 48 hours. These gas and oil drillers only need open a few valves to crush the price right back down. That is the real issue. Of course nat will move on the draw down but how long can it hold with so many players willing to open the spigot.
If you notice the Woburn Mass facility has an opening for 2nd shift. They have been running two shifts for several months. I believe they manufacture the Claros device. Thought they also made the cassettes but not sure any more. Like the idea they feel it necessary to run two shifts to ready for sales.
Imminent BK, no court would grant a Bk with their unused unlevered 4B credit line, and couple Billion in cash. Quit talking nonsense.
Not sure what % of leases and wells were sold, but 5.8B for a slice of the company. So are they saying 10-12% of chk is worth 5.8 Billion, and the remainder 7.4 B. Does not add up.
Figure too the last asset sale, 4.975 billion, plus this 840m = 5.815 billion cash infusion. Hope they pay down a lot of debt. Not sure what % of assets or wells these two sales are, but that cash for assets could eliminate debt if they keep it up. Just a smaller, leaner, more profitable company. If they sold off another 5.8B of assets, chk would be in great shape.
They should keep this up, 7-8 more times and be debt free and still have 80% of their assets. Of course 7-8 more sales of this nature is more than the market cap, but that means little. Still the value of each 20% of chk sold piece meal is = to the current cap, it could be good for share holders if they sold more small chunks.
Chk bonds are spread out over a couple decades, so yes they have heavy debt, but manageable debt. Only 1.5B due in next two years, they can pay both bonds off easily with this deal, and cash on hand. So the real question is, can they handle the interest on their debt, and that will not be an issue.
Can they pay off all their debt today? No. Most cannot write a check to pay off their mortgage in one payment either. This deal gives them room on covenants, and flexibility on debt reduction, firming up the balance sheet.
With cash on hand, plus this new cash infusion, they can payoff both 2016 and 2017 bonds, and still have over 1.5 billion cash on hand. Good move, though the cash per acre was not what it would have been a year ago.